The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo； materials and methods for editing a RHO gene in a human cell； and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene； one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene； and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.
